ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Zai Lab Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$24.06+0.87 (+3.75%)
Close on Oct 19, 2026
- Market cap
- $26.87B
- P/E (TTM)
- –
- Dividend yield
- –
Zai Lab statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Zai Lab | Industry median |
|---|---|---|
| Market Cap | $3.74B | $164.85M |
| Enterprise Value | $3.36B | $87.06M |
| PS Ratio | 8.31 | 3.60 |
| PB Ratio | 6.16 | 2.03 |
| P/TBV Ratio | 7.17 | 2.31 |
Enterprise value
| Measure | Zai Lab | Industry median |
|---|---|---|
| EV / Sales | 7.47 | 2.43 |
Income (trailing twelve months)
| Measure | Zai Lab | Industry median |
|---|---|---|
| Revenue | $449.61M | $57.94M |
| Gross Profit | $254.07M | $90.47M |
| Operating Income | -$264.10M | -$21.44M |
| Pretax Income | -$190.72M | -$14.45M |
| Net Income | -$188.21M | -$22.46M |
| EBITDA | -$248.17M | -$16.91M |
| EPS (Diluted) | -$0.18 | -$0.83 |
Margins
| Measure | Zai Lab | Industry median |
|---|---|---|
| Gross Margin | 56.5% | 52.3% |
| Operating Margin | -58.7% | -44.5% |
| Pretax Margin | -42.4% | -13.0% |
| Profit Margin | -41.9% | -39.2% |
| EBITDA Margin | -55.2% | -31.3% |
| FCF Margin | -31.0% | -8.85% |
Returns
| Measure | Zai Lab | Industry median |
|---|---|---|
| Return on Equity (ROE) | -26.9% | -53.1% |
| Return on Assets (ROA) | -16.8% | -41.0% |
| Return on Invested Capital (ROIC) | -90.4% | -32.0% |
| Return on Capital Employed (ROCE) | -40.9% | -37.8% |
Growth
| Measure | Zai Lab | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 5.10% | 6.01% |
| Revenue Growth (3Y CAGR) | 28.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 56.5% | 6.42% |
Balance sheet
| Measure | Zai Lab | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $617.52M | $62.42M |
| Total Debt | $238.10M | $120.13M |
| Net Cash (Debt) | $379.42M | $15.68M |
| Net Cash Per Share | $0.24 | $0.66 |
| Equity (Book Value) | $607.04M | $48.79M |
| Book Value Per Share | $0.39 | $1.36 |
| Tangible Book Value | $521.26M | $23.06M |
| Working Capital | $485.45M | $75.77M |
Financial position
| Measure | Zai Lab | Industry median |
|---|---|---|
| Current Ratio | 2.13 | 3.30 |
| Quick Ratio | 1.60 | 2.39 |
| Debt / Equity | 0.39 | 0.51 |
| Interest Coverage | -44.13 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Zai Lab | Industry median |
|---|---|---|
| Operating Cash Flow | -$133.38M | -$12.35M |
| Capital Expenditures | -$6.19M | -$1.06M |
| Free Cash Flow | -$139.57M | -$20.28M |
| FCF Per Share | -$0.09 | -$0.42 |
Efficiency
| Measure | Zai Lab | Industry median |
|---|---|---|
| Asset Turnover | 0.40 | 0.38 |
| Inventory Turnover | 2.56 | 2.67 |
| Revenue Per Employee | $252.03K | $398.96K |
| Profits Per Employee | -$105.50K | -$703.34K |
| Employee Count | 1,784 | 74 |
Dividends and yields
| Measure | Zai Lab | Industry median |
|---|---|---|
| Earnings Yield | -5.04% | -22.7% |
| FCF Yield | -3.74% | -9.07% |
Shares
| Measure | Zai Lab | Industry median |
|---|---|---|
| Shares Outstanding | 1,553,110,000 | 58,179,650 |
| Shares Change (YoY) | 6.00% | 11.1% |
| Shares Change (QoQ) | 1.10% | 0.54% |
| Float | 1,542,700,000 | 49,173,100 |
| Shares Held by Insiders | 0.67% | 11.6% |
| Shares Held by Institutions | 2.79% | 59.4% |
Taxes
| Measure | Zai Lab | Industry median |
|---|---|---|
| Income Tax | -$2.51M | $91.50K |
Scores
| Measure | Zai Lab | Industry median |
|---|---|---|
| Altman Z-Score | 1.39 | -0.24 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -2.36 | -2.62 |
Calculated by StockData from Zai Lab's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.